Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.venusremedies.com | |
Market Cap | 203.18 Cr. | |
Enterprise Value(EV) | 179.37 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 11.78 | Trailing Twelve Months Ending 2022-12 |
Price-Earning Ratio (PE) | 12.83 | Trailing Twelve Months Ending 2022-12 |
Industry PE | 32.22 | Trailing Twelve Months Ending 2022-12 |
Book Value / Share | 339.72 | Trailing Twelve Months Ending 2022-12 |
Price to Book Value | 0.44 | Calculated using Price: 151.15 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 1.34 Cr. | 13,366,988 Shares |
FaceValue | 10 | |
Company Profile | ||
Venus Remedies incorporated in 1989, is a pharmaceutical manufacturing company. The company provides formulations in area of anti-biotics and oncological therapeutics. |
1 Day |
|
-3.91% |
1 Week |
|
-7.72% |
1 Month |
|
-16.84% |
3 Month |
|
-26.87% |
6 Month |
|
-31.70% |
1 Year |
|
-53.48% |
2 Year |
|
-14.51% |
5 Year |
|
+78.03% |
10 Year |
|
-38.02% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 15.38 | 1.12 | 0.38 | -4.13 | -8.18 | -8.23 | -3.05 | 17.40 | 9.85 | |
Return on Capital Employed (%) | 14.06 | 5.74 | 5.35 | 2.00 | 1.17 | -0.67 | 0.90 | 12.37 | 7.89 | |
Return on Assets (%) | 8.29 | 0.62 | 0.20 | -2.12 | -4.05 | -3.85 | -1.45 | 10.30 | 7.18 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 462 | 457 | 438 | 389 | 362 | 333 | 323 | 400 | 440 | 451 | |
Non Curr. Liab. | 162 | 222 | 212 | 180 | 158 | 137 | 96 | 58 | 46 | 48 | |
Curr. Liab. | 211 | 163 | 193 | 197 | 230 | 264 | 225 | 97 | 93 | 84 | |
Minority Int. | |||||||||||
Equity & Liab. | 834 | 841 | 843 | 765 | 751 | 733 | 644 | 556 | 579 | 583 | |
Non Curr. Assets | 562 | 608 | 566 | 506 | 491 | 467 | 350 | 322 | 301 | 287 | |
Curr. Assets | 272 | 233 | 277 | 259 | 260 | 265 | 294 | 234 | 278 | 295 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 834 | 841 | 843 | 765 | 751 | 733 | 644 | 556 | 579 | 583 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
Net Sales | 542 | 464 | 418 | 400 | 372 | 322 | 339 | 548 | 599 | 542 | |
Other Income | 0 | 1 | 2 | 4 | 2 | 6 | 5 | 20 | 8 | 9 | |
Total Income | 542 | 465 | 420 | 404 | 375 | 328 | 345 | 568 | 607 | 551 | |
Total Expenditure | -403 | -375 | -337 | -349 | -333 | -289 | -299 | -494 | -537 | -501 | |
PBIDT | 139 | 90 | 83 | 55 | 42 | 39 | 46 | 73 | 70 | 50 | |
Interest | -29 | -41 | -38 | -36 | -36 | -25 | -13 | -13 | 0 | 0 | |
Depreciation | -40 | -46 | -42 | -40 | -34 | -34 | -32 | -35 | -34 | -32 | |
Taxation | -5 | 3 | -2 | 5 | -3 | 1 | -2 | 13 | 4 | -3 | |
Exceptional Items | -9 | -9 | 23 | ||||||||
PAT | 64 | 5 | 2 | -17 | -31 | -29 | -10 | 62 | 41 | 16 | |
Minority Interest | |||||||||||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 64 | 5 | 2 | -17 | -31 | -29 | -10 | 62 | 41 | 16 | |
Adjusted EPS | 56 | 5 | 1 | -14 | -25 | -23 | -8 | 50 | 30 | 12 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 52 | 53 | 68 | 47 | 59 | 31 | 45 | 78 | 132 | 41 | |
Cash Fr. Inv. | -104 | -95 | -67 | 3 | -18 | -11 | -11 | -5 | 56 | -17 | |
Cash Fr. Finan. | 55 | 40 | -1 | -46 | -44 | -39 | -35 | -73 | -162 | -9 | |
Net Change | 3 | -2 | -1 | 3 | -4 | -20 | -1 | 0 | 26 | 15 | |
Cash & Cash Eqvt | 6 | 4 | 4 | 7 | 4 | -20 | 3 | 2 | 29 | 43 |
Thu, 02 Feb 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper publication of Financial Results for the period ended on 31.12.2022. |
Thu, 02 Feb 2023
Announcement under Regulation 30 (LODR)-Press Release / Media Release Venus Remedies bags Great Place To Work certification again |
Mon, 30 Jan 2023
Submission Of Unaudited Financial Results For The Period Ended On 31St December 2022 Please find enclosed herewith Unaudited Financial Results for the period ended on 31st December 2022 along with Limited Review report which were taken on record by the Board of Directors at its meeting held on 30th January 2023. |
Fri, 03 Feb 2023 |
|
|
|
|
|